Navigation Links
BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
Date:2/1/2011

and joint abnormalities, which limit mobility and endurance. Malformation of the thorax impairs respiratory function, and odontoid hypoplasia and ligamentous laxity cause cervical spinal instability and potential cord compression. Other symptoms may include hearing loss, corneal clouding, and heart valvular disease. Initial symptoms often become evident in the first five years of life.  Depending on severity of the disease, age of diagnosis will vary.

The rate of incidence of MPS IVA is as yet unconfirmed and varies among different populations but estimates vary between 1 in 200,000 live births and 1 in 250,000 live births. There are several studies that have documented the incidence as high as 1 in 76,000 live births in Northern Ireland. The estimated prevalence is between 1,000 and 1,500 patients in the U.S., EU and Japan and between 1,500 to 2,000 patients in the rest of the world for a total of 2,500 to 3,500 patients. Over 1,000 MPS IVA patients worldwide have been identified through The International Morquio Organization (IMO) survey and the BioMarin MorCAP registry program.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Synd
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. BioMarin Announces FDA Approval for Kuvan
3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
8. BioMarin to Present at the Oppenheimer Healthcare Conference
9. BioMarin Announces Third Quarter 2009 Financial Results
10. BioMarin to Acquire LEAD Therapeutics
11. BioMarin to Present at the Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... Introduction of new ... tools for radiosurgery/SBRT   The "Elements" ... enhancing the workflow for difficult to treat indications ... - comes full circle with the introduction of ... Elements enable on-the-fly generation of consistent treatment plans ...
(Date:4/24/2015)... , April 24, 2015 /CNW/ - T-Bird Pharma Inc. ... on developing premium quality medical marijuana products and a ... for Medical Purposes Regulations ( Canada ) ... certain of its shareholders, has closed the transaction announced ... Medna has acquired (the "Escrow Transfer") a total of ...
(Date:4/23/2015)... Lifesciences Corporation (NYSE: EW ), the global leader ... today reported net income for the quarter ended March 31, ... Net income for the same period a year earlier ... non-GAAP net income was $82.1 million, or $0.76 per ... ended March 31, 2015 increased 13.0 percent to $590.3 million ...
Breaking Medicine Technology:Brainlab Introduces New Generation of VMAT* for Brain and Spine at 3rd ESTRO in Barcelona 2T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences 2T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences 3Edwards Lifesciences Reports First Quarter Results 2Edwards Lifesciences Reports First Quarter Results 3Edwards Lifesciences Reports First Quarter Results 4Edwards Lifesciences Reports First Quarter Results 5Edwards Lifesciences Reports First Quarter Results 6Edwards Lifesciences Reports First Quarter Results 7Edwards Lifesciences Reports First Quarter Results 8Edwards Lifesciences Reports First Quarter Results 9Edwards Lifesciences Reports First Quarter Results 10Edwards Lifesciences Reports First Quarter Results 11Edwards Lifesciences Reports First Quarter Results 12Edwards Lifesciences Reports First Quarter Results 13Edwards Lifesciences Reports First Quarter Results 14Edwards Lifesciences Reports First Quarter Results 15Edwards Lifesciences Reports First Quarter Results 16
... 2011 Pennsylvania Association of Medical Suppliers (PAMS) ... Thompson (R-Centre) and Jason Altmire, (D-Allegheny) that would ... medical equipment.  H.R. 1041, titled the "Fairness in ... patient groups and consumer organizations, including the Three ...
... ViroPharma Incorporated (Nasdaq: VPHM ) today ... Use (CHMP) of the European Medicines Agency (EMA) has ... March 2011 recommending approval of a Centralized Marketing Authorization ... with hereditary angioedema (HAE) for routine prevention, pre-procedure prevention ...
Cached Medicine Technology:Bi-Partisan Legislation Introduced Would Repeal Controversial Medicare 'Competitive Bidding' Requirements for Home Medical Equipment 2Bi-Partisan Legislation Introduced Would Repeal Controversial Medicare 'Competitive Bidding' Requirements for Home Medical Equipment 3Bi-Partisan Legislation Introduced Would Repeal Controversial Medicare 'Competitive Bidding' Requirements for Home Medical Equipment 4ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union 2ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union 3ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union 4ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union 5ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union 6
(Date:4/24/2015)... Carvers' goal is to help an ... day in Breck. , Conveniently located in the ... from Breckenridge, this family-owned place since 1995, has ... rentals ( http://www.breckenridgeskishop.com/en/rent-equipment ) and more. , ... in May 2015. With style and function progressing ...
(Date:4/24/2015)... 24, 2015 On February 21st, 2015, ... an interview with ItsNotAboutMe.TV contributor Karen Salkin at Durkin ... treatment center for addiction, of which Wickstrom is the ... throughout the year, the EcoLuxe Lounge is a gathering ... and socially conscious products and services. Among the many ...
(Date:4/24/2015)... Anchor Health Administrators (Anchor), specialists in Long-Term Care ... exclusive agreement with LTC Solutions for All LLC (SFA) ... , Anchor has more than 18 years of experience ... and is currently the designated advocate for the American ... member benefit. , “I am very pleased to be ...
(Date:4/24/2015)... Joseph, Missouri (PRWEB) April 24, 2015 ... for veterinarians , UGA is now proud to be ... the care of 16,000 animals a year. This partnership ... care for their animals. , After providing an ... Missouri Veterinary Medical Teaching Hospital (VMTH) wanted to increase ...
(Date:4/24/2015)... “ Opera ” was featured on NewsWatch as part of ... technology products available to consumers. Andrew Tropeano, a technology expert ... with viewers how this is the fastest way to surf ... not be in existence. But each web browser is slightly ... different. Celebrating their 20th anniversary this year, Opera connects over ...
Breaking Medicine News(10 mins):Health News:Carvers Breckenridge Bike Rentals Offers Demo Mountain, Tandem, Bike Path Cruiser & JR. Bikes in May 2015 2Health News:Karen Salkin Talks with Per Wickstrom at the 2015 EcoLuxe Lounge and the "Salute to the Oscars" Celebration 2Health News:University of Missouri Veterinary Medical Teaching Hospital Teams with UGA 2Health News:A Web Browser That Connects over 350 Million People was Featured on NewsWatch Television 2
... irregularities are at greater risk of heart-rhythm abnormality: study ... who have severe sleep-related breathing problems are at increased ... , The study included 2,911 men who underwent sleep ... episodes of paused or shallow breathing during sleep were ...
... (NYSE: HGR ) announced today that it plans to ... the second quarter ending June 30, 2009, on Tuesday, July 28, ... The conference call is scheduled to begin at 9:00 a.m., EDT, ... 1-800-931-9710. In addition, a replay will be available until August 5, ...
... U.S. patent infringement lawsuit was filed on June 10, ... America, Inc. The lawsuit, brought by Aperio Technologies, ... of Delaware, accuses products incorporating Hamamatsu Photonics K.K. NanoZoomer(R) ... and 7,518,652. , , The lawsuit follows a ...
... YORK, June 23 FamilyCord , one of ... their title sponsorship of the WBLI 106.1 Baby Shower event where ... for a day of fun, prizes, and education on June 28. ... storing cord blood to protect newborns against 70 life-threatening diseases. Leading ...
... June 23 The National Medical Association (NMA) congratulates President ... their work with PhRMA to bring down health care costs ... the adoption of Medicare Part D has been a tremendous ... the system," said Dr. Mohammad N. Akhter, Executive Director of ...
, Journalists and other readers should disregard the news release, PHT Names VP to Lead Sales of A-Claim Payment Solution for Doctors, Hospitals, issued 23-Jun-2009. The release was transmitted prema...
Cached Medicine News:Health News:Sleep Disorders Linked to Arrhythmias 2Health News:U.S. Patent Infringement Lawsuit Filed by Aperio Technologies, Inc. 2
Suspend® Tutoplast® Processed Fascia Lata is your naturally safe and strong choice for pelvic floor reconstruction. Suspend comes from a dense matrix of collagen bundles and transverse fasc...
... Bard® Dermal Allograft ... of most pelvic floor ... highly resistant to suture ... and serves as a ...
... Viral RNA Mini Kit allows ... from cell-free fluid samples. Examples ... can be isolated with this ... limited to, RNA from hepatitis ...
The PersonalLAB junior is an automated microplate analyzer capable of fully automating immunoenzymatic techniques using a microplate format, per the reagent manufacturer's instruction for use and spe...
Medicine Products: